Press release
Muscular Dystrophies Market Top Key Players are Catabasis Pharmaceuticals, Biogen, FibroGen, EspeRare Foundation, Milo Biotechnology, Italfarmaco SpA, PTC Therapeutics, Pfizer, Roche, Sarepta Therapeutics, and Santhera Pharmaceuticals
Muscular dystrophies (MD) are a spectrum of genetic disorders characterized by muscle weakness that, which in severe forms of the disease can lead to loss of gait and premature death. Doctors share common histological features, such as reduced muscle fiber size, degeneration, and the presence of connective tissue and adipose tissue instead of muscle. Duchenne muscular dystrophy (DMD) is the most common subtype in the children, while myotonic dystrophy is more common in adults.
Browse report brief and TOC @ https://www.researchcosmos.com/reports/muscular-dystrophies-in-12-major-markets-forecast-report-2017-2027/803483881
Ataluren targets a subset of patients with DMD and has been available in selected markets after its European approval in 2014, eteplirsen (Sarepta’s Exondys 51) received conditional approval in the United States in 2016 and targets a different group of patients with DMD who share a genetic mutation similar to the basis of their disease. Although both drugs target the underlying cause of the disease and, therefore, could alter its course, the efficacy observed so far in clinical trials seems modest and the unmet need for effective therapies that modify the disease.
The unmet need for effective treatments capable of significantly delaying or stopping progressive muscle degeneration in DMD, as well as in other severe and moderate cases is high. It is expected that the growing research and development, the introduction of new therapies, the growing demand for effective therapies in patients and an increase in the prevalence of the disease will drive the growth of the therapeutics for muscular dystrophy market. According to the Centers for Disease Control and Prevention, in 2016, the prevalence of Duchenne muscular dystrophy and Becker muscular dystrophy (DBMD) was 1 in 7,250 men aged 5 to 24 years. The increasing prevalence of chronic diseases such as cardiovascular, neurovascular and arthritis is another supporting factor for the growth of this disease. According to the World Health Organization, cardiovascular diseases caused 17.7 million deaths in 2015, representing 31% of all deaths worldwide. However, stricter regulations for product approval and high product costs may limit the market expansion.
Request free sample @ https://www.researchcosmos.com/request/muscular-dystrophies-in-12-major-markets-forecast-report-2/803483881
North America accounts for the largest base of sufferers with this ailment. Innovation in new products and government awareness programs will increase the awareness of people in North America about the issues related with the disease. Muscular Dystrophy of United Parent Projects has launched the Duchenne World Awareness Day on September 7 that aims to raise awareness about the disease and its consequences. Europe is the second largest market for muscular dystrophies. The Asia-Pacific is expected to grow faster due to rapid population growth and the increasing prevalence of chronic diseases. Increased health care coverage and increased investment in research and development along with the growing awareness of the population and greater coverage of public and private healthcare will create huge opportunities for the pharmaceutical companies to develop effective drugs for treatment.
Inquire Before Buying @ https://www.researchcosmos.com/inquire/muscular-dystrophies-in-12-major-markets-forecast-report-2/803483881
Key players In Muscular Dystrophies Market:
AMO Pharma, Akashi Therapeutics, aTyr Pharma, Catabasis Pharmaceuticals, Biogen, FibroGen, EspeRare Foundation, Milo Biotechnology, Italfarmaco SpA, PTC Therapeutics, Pfizer, Roche, ReveraGen BioPharma, Sarepta Therapeutics, and Santhera Pharmaceuticals are the major players of the market.
About Us:
Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.
Contact:
Kevin Stewart
kevin@researchcosmos.com
Global Sales Manager
Research Cosmos
www.researchcosmos.com
+1 888 709 8757
LinkedIn - https://www.linkedin.com/company/market-research-cosmos
Twitter - https://twitter.com/researchcosmos
Google+ - https://plus.google.com/109756852849129986268
Facebook - https://www.facebook.com/researchcosmos/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Muscular Dystrophies Market Top Key Players are Catabasis Pharmaceuticals, Biogen, FibroGen, EspeRare Foundation, Milo Biotechnology, Italfarmaco SpA, PTC Therapeutics, Pfizer, Roche, Sarepta Therapeutics, and Santhera Pharmaceuticals here
News-ID: 1289131 • Views: …
More Releases from Research Cosmos
Mobile Phone Insurance Market Size to Reach USD 32.24 Bn By 2025
The size of the Global mobile phone insurance market is estimated to reach USD 32.24 billion by 2025, growing at a CAGR of 12.5%, as per the recently published report by Research Cosmos. It is worth to claim insurance for mobile phones as we are spending a lot of money on purchasing. The policies include accidental damage, water damage, and screen cracking.
Browse details of the report @ https://www.researchcosmos.com/reports/mobile-phone-insurance-market/199557834
Growing utilization…
Social Employee Recognition Systems Market Predicted to grow at a CAGR of xx By …
Social Employee Recognition Systems Market Analysis Size, Growth rate and Overview:
Social Employee Recognition Systems Market was valued at USD xx million in 2018 and is expected to reach almost USD xx million by the end of 2025, growing at a CAGR of around xx% over the predicted period.
Throughout the world, social employee recognition systems have expanded dramatically to address the need to move away from traditional methods and programs of…
More Releases for Muscular
Limb Girdle Muscular Dystrophy Pipeline Insight 2025: Advancing Genetic and Rege …
DelveInsight's "Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2025" report provides a deep dive into the evolving therapeutic landscape of LGMD, a group of genetically inherited muscular disorders characterized by progressive weakness in the hip and shoulder muscles. With more than 25 active pipeline candidates targeting various LGMD subtypes, the field is witnessing a shift toward personalized gene therapies and precision treatments.
Recent advances have focused on gene replacement, exon…
Evolving Market Trends In The Spinal Muscular Atrophy Industry: Revolutionizing …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected Spinal Muscular Atrophy Market Size During the Forecast Period?
Recent years have witnessed a swift expansion of the spinal muscular atrophy market size. The market is projected to surge from $3.53 billion in 2024 to $4.01 billion in 2025, escalating at a compound annual growth rate (CAGR) of 13.5%. The…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Becker Muscular Dystrophy Market Research Report 2032
DelveInsight's "Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Becker Muscular Dystrophy (BMD), historical and forecasted epidemiology as well as the Becker Muscular Dystrophy (BMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder that results in progressive deterioration of limbs, cardiac and skeletal muscles. However,…
Increasing cases of Spinal Muscular Atrophy will accelerate the Spinal Muscular …
Precision Business Insights published a research report on "Spinal Muscular Atrophy Management Market: By Type of Disease (Type-I, Type-II, Type-III, Type-IV), By Management (Gene Therapy, Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2027", The Global Muscular Atrophy Management Market is anticipated to grow at considerable level during forecast period 2021-2027. Spinal Muscular Atrophy Management Market was valued at USD 1.3 Billion in 2020…
Spinal Muscular Atrophy Market is Driven by Rising Number of People Affected wit …
The global spinal muscular atrophy market witnesses substantial competition with the presence of a considerable number of market participants of varying sizes, says Transparency Market Research (TMR) in a new market study.
Read Report Overview - https://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html
Savvy players are engaged in developing novel drug formulations, the success rate of which impacts market share, and trust of these companies among consumers. For such initiatives, large players are partnering with regional companies to…
